Month: April 2014
Australian shark fear survey shows little support for culling
Australia ranks high in global charts of shark attacks and is currently running an aggressive culling drive against the marine predator, but a new survey says many Australians aren’t really that worried about them. “The assumption is that the public is afraid that when shark bites happen that they react emotionally and that they are looking for an immediate response,” University of Sydney shark expert Christopher Neff told Reuters. “My data and what the public has said refutes that,” he said of the survey, which asked visitors how the government should respond to shark attacks. There have been 892 shark attacks in Australia since records began in 1791, 217 of which have been fatal.
Here's How Fast Food And Exercise Habits Vary Around America
5 Lessons About Exercise You Can Learn From Your Dog | Summer Tomato
Sport Information Resource Centre (SIRC): Is massage effective for exercise recovery?
Ole Lenku defends Kasarani vetting exercise of terror suspects
Military plans exercise in sky above central Iowa
Two moms, a baby and a legal first for U.S. gay marriage
By Joan Biskupic KNOXVILLE, Tennessee (Reuters) – Last month a baby in Tennessee made history: Emilia Maria Jesty was the first child born in the state to have a woman listed on the birth certificate as her "father." The marital status of the baby's parents was the subject of a flurry of court filings up to a few days before her birth. Valeria Tanco and Sophy Jesty were wed in New York, a state that recognizes gay marriage, and moved to Tennessee, which does not. Depending on the pace of rulings, as early as next year Tanco and Jesty's case or a similar challenge could reach the Supreme Court.
Mirwaiz calls for boycott of polls,brands it a futile exercise
FDA halts Halozyme’s pancreatic cancer study
(Reuters) – Halozyme Therapeutics Inc said the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial. The company's shares fell about 3 percent to $8.06 in trading before the bell. Halozyme said on April 4 that it had temporarily stopped the trial after the recommendation of an independent safety board, which was assessing a possible difference in the rate of blood clots found in patients receiving Halozyme's treatment and those receiving approved cancer treatments. The company said on Wednesday that it was gathering information related to the issue and would provide it to the safety monitoring committee and the FDA.